WO2001009134A1 - Purine derivatives inhibitors of tyrosine protein kinase syk - Google Patents
Purine derivatives inhibitors of tyrosine protein kinase syk Download PDFInfo
- Publication number
- WO2001009134A1 WO2001009134A1 PCT/EP2000/007311 EP0007311W WO0109134A1 WO 2001009134 A1 WO2001009134 A1 WO 2001009134A1 EP 0007311 W EP0007311 W EP 0007311W WO 0109134 A1 WO0109134 A1 WO 0109134A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- ring
- group
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Definitions
- This invention relates to organic compounds, their preparation and their use as pharmaceuticals.
- the present invention relates to:
- X is an oxygen or sulfur atom or a group NR 5 ,
- R 1 is an alkyl, alkenyl, cycloalkyl, benzocycloalkyl, cycloalkylaikyl or aralkyl group which optionally may be substituted by hydroxy, alkoxy, carboxy or alkoxycarbonyl or, when X is NR 5 , R 1 may alternatively be a heterocyclyl group or a group of formula
- R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are each independently hydrogen, halogen, alkyl, haloalkyl, alkoxy, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, -N(R 9 )R 10 , - SOaNfR ⁇ R 12 , Q-C 4 -alkylene-SO 2 N(R l1 )R 12 or -CON(R 13 )R M or, when two of R 2 , R 3 and R 4 , or two of R 6 , R 7 and R 8 , are attached to adjacent carbon atoms on the indicated benzene rings, they denote, together with the carbon atoms to which they are attached, a carbocyclic group having 5 to 10 ring atoms or a heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur, R 5 is hydrogen or alkyl,
- R 9 is hydrogen or alkyl and R 10 is hydrogen, alkyl or -COR 15 where R 15 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, carboxyalkyl or alkoxycarbonylalkyl, or R 9 and R 10 , together with the nitrogen atom to which they are attached, denote a heterocyclic group having 5 or 6 ring atoms of which one or two are hetero atoms selected from nitrogen, oxygen and sulfur,
- R 11 is hydrogen or alkyl and R 12 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl or alkoxycarbonylalkyl, or R 11 and R 12 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 or 6 ring atoms of which one or two are hetero atoms selected from nitrogen, oxygen and sulfur, and
- R and R 14 are each independently hydrogen or alkyl; particularly to compounds of formula I in free or pharmaceutically acceptable salt form for use as pharmaceuticals;
- R 9 , R 10 , R 11 , R 12 , R 13 or R 14 in R 2 , R 3 or R 4 may be the same as, or may differ from, the respective group in R 6 , R 7 or R 8 .
- the present invention provides compounds of formula I as hereinbefore defined in free or salt form, with the exception of 2-( ⁇ -n-butylanilino)-6-methoxypurine, 2- (p-n-butylanilino)-6-(methylthio)purine, 2,6-di(phenylamino)purine, 2,6-di(p- tolylamino)purine, and 2-(p-tolylamino)-6-(phenylamino)purine.
- the present invention provides compounds of formula I as hereinbefore defined in free or salt form, with the exception of compounds of formula I where (i) X is oxygen or sulfur, R 1 is alkyl, two of R 2 , R 3 and R 4 are hydrogen and one of R 2 , R 3 and R 4 is alkyl and ( ⁇ ) X is NH, R 1 is a group of formula II in which two of R 6 , R 7 and R 8 are hydrogen and the remaining one is hydrogen or alkyl, one of R 2 , R 3 , and R 4 is hydrogen and the remaining two are each hydrogen or alkyl.
- the present invention provides a compound of formula I as hereinbefore described in free or salt form in which (a) X is NR 5 and R 1 , R 2 , R 3 , R 4 and R 5 are as hereinbefore defined, with the proviso that when R 1 is a group of formula U, R 6 , R 7 and R 8 are each independently halogen, haloalkyl, alkoxy, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, -N(R 9 )R 10 , - SO 2 N(R")R 12 , C C 4 -alkylene-SO 2 N(R 11 )R 12 or -CON(R 13 )R 14 or, when two of R 6 , R 7 and R 8 are attached to adjacent carbon atoms on the indicated benzene ring, they denote, together with the carbon atoms to which they are attached, a carbocyclic group having 5 to 10 ring atoms or a hetero
- X is oxygen or sulfur and R 1 , R 2 , R 3 and R 4 are as hereinbefore defined, with the proviso that when R 1 is alkyl, R 2 , R 3 and R 4 are each independently hydrogen, halogen, alkoxy, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, -N(R 9 )R 10 , - SO 2 N(R")R 12 , Q-C 4 -alkylene-SO 2 N(R 11 )R 12 or -CON(R 13 )R 14 or, when two of R 2 , R 3 and R 4 are attached to adjacent carbon atoms on the indicated benzene rings, they denote, together with the carbon atoms to which they are attached, a carbocyclic group having 5 to 10 ring atoms or a heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur.
- Alkyl denotes straight chain or branched alkyl, which may be, for example, to o- alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, straight or branched pentyl, straight or branched hexyl, straight or branched heptyl, straight or branched nonyl or straight or branched decyl.
- alkyl is to C 4 -alkyl.
- Alkoxy denotes straight chain or branched alkoxy and may be, for example, to C r ⁇ alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, or straight or branched pentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy or decyloxy.
- alkoxy is to C 4 -alkoxy.
- Alkenyl means straight chain or branched alkenyl, which may be, for example, C 2 to o-alkenyl such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, or straight or branched pentenyl, hexenyl, heptenyl, octenyl, nonenyl or decenyl.
- Preferred alkenyl is C 2 to C 4 -alkenyl.
- Cycloalkyl means C 3 to C TO -cycloalkyl having 3 to 8 ring carbon atoms and may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cycloheptyl, any of which can be substituted by one, two or more C r C 4 alkyl groups, particularly methyl groups.
- cycloalkyl is C 3 -C ⁇ rcycloalkyl.
- Benzocycloalkyl means cycloalkyl, e.g. one of the C 3 to o cycloalkyl groups mentioned hereinbefore, attached at two adjacent carbon atoms to a benzene ring.
- benzocycloalkyl is benzo-Cs-C ⁇ -cycloalkyl, especially benzocyclohexyl
- Cycloalkylaikyl means to o-cycloalkyl -C J -C JO alkyl where the C 3 to d 0 -cycloalkyl group has 3 to 8 ring carbon atoms and may be, for example, one of the Ci- o-alkyl groups mentioned hereinbefore, particularly one of the C r C 4 -alkyl groups, substituted by one of the C 3 -C 10 -cycloalkyl groups mentioned hereinbefore.
- cycloalkylaikyl is C 3 - -cycloalkyl-CrC 4 -alkyl.
- Alkyl means C 6 -C ⁇ 0 -aryl-C ⁇ -C ⁇ o alkyl and may be, for example, one of the -Cio-alkyl groups mentioned hereinbefore, particularly one of the C C 4 -alkyl groups, substituted by phenyl, tolyl, xylyl or naphthyl.
- aralkyl is phenyl-Cj-C 4 -alkyl, particularly benzyl or 2-phenyl ethyl.
- Heterocyclyl means a monovalent heterocyclic radical having up to 20 carbon atoms and one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, the radical optionally having an alkyl, alkylcarbonyl, hydroxyalkyl, alkoxyalkyl or aralkyl group attached to a ring carbon or nitrogen atom and being linked to the remainder of the molecule through a ring carbon atom, and may be, for example, a radical, preferably a monocyclic radical, with one nitrogen, oxygen or sulfur atom such as pyrryl, pyridyl, piperidyl, furyl, tetrahydrofuryl or thienyl, or a radical, preferably a monocyclic radical, with two hetero atoms selected from nitrogen, oxygen and sulfur, such as imidazolyl, pyrimidinyl, piperazinyl, oxazolyl, isoxazolyl, thiazolyl, morpholinyl or thiomorpholin
- heterocyclyl is a monocyclic radical having 5 or 6 ring atoms and one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, in the ring and optionally substituted on a ring nitrogen atom by -C -alkyl, hydroxy-Ci-C 4 -alkyl, -C 4 - alkylcarbonyl or phenyl- -C 4 -alkyl.
- Alkoxyalkyl means straight chain or branched alkyl substituted by one or more alkoxy groups and may be, for example, a Ci-Cio-alkoxy-Ci-Cio-alkyl group, such as one of the - n-alkyl groups, particularly one of the Q-C 4 -alkyl groups, mentioned hereinbefore substituted by one of the -Cio-alkoxy groups, preferably one of the C ⁇ -C 4 -alkoxy groups, mentioned hereinbefore.
- alkoxyalkyl is C C 4 -alkoxy-C ⁇ -C 4 alkyl.
- Carboxyalkyl means straight chain or branched alkyl, for example C ⁇ -C 10 -alkyl such as one of the Ci-Cio-alkyl groups mentioned hereinbefore, substituted, preferably on a primary carbon atom, by a carboxyl group.
- carboxyalkyl is carboxy-Q-C 4 - alkyl.
- Alkylcarbonyl means a group R 16 CO where R ⁇ is alkyl, for example -Cjo-alkyl such as one of the Cr 0 -, preferably -C 4 -, alkyl groups mentioned hereinbefore.
- alkylcarbonyl is C C 4 -alkylcarbonyl, i.e. R 16 CO where R 16 is -C 4 -alkyl.
- Alkoxycarbonyl means a group R 17 CO where R 17 is an alkoxy group, for example a - o alkoxy group such as one of the - o, preferably -C , alkoxy groups mentioned hereinbefore.
- alkoxycarbonyl is -C 4 -alkoxycarbonyl, i.e. R 17 CO where R 17 is -C 4 -alkoxy.
- Alkoxycarbonylalkyl means straight or branched chain alkyl, for example a Cr- o alkyl group such as one of the C C 10 -, preferably -C 4 -, alkyl groups mentioned hereinbefore, substituted by an alkoxycarbonyl group as hereinbefore defined.
- alkoxycarbonylalkyl is CrC 4 -alkoxy-carbonyl-C ⁇ -C -alkyl.
- Haloalkyl means straight chain or branched alkyl, for example Cr o-alkyl such as one of the C I -C JO - alkyl groups mentioned hereinbefore, substituted by one or more, for example one, two or three, halogen atoms, preferably fluorine or chlorine atoms.
- haloalkyl is -C 4 -alkyl substituted by one, two or three fluorine or chlorine atoms.
- Hydroalkyl means straight chain or branched alkyl, for example -Cio-alkyl such as one of the - o-alkyl groups mentioned hereinbefore, substituted by one, two or three hydroxyl groups.
- hydroxyalkyl is -C 4 -alkyl substituted by one hydroxyl group.
- R 2 , R 3 and R 4 , or one of R 6 , R 7 and R 8 is hydrogen and the second and third of R 2 , R 3 and R 4 , or the second and third of R 6 , R 7 and R 8 , are attached to adjacent carbon atoms in the respective benzene ring and together with said adjacent carbon atoms denote a carbocyclic group or heterocyclic group
- the second and third of R 2 , R 3 and R 4 , or the second and third of R 6 , R 7 and R 8 may denote, together with the benzene ring to which they are attached, a CjpCts-carbocyclic group such as indenyl or naphthyl, optionally substituted by one or more -C 4 -alkyl or C C 4 -alkoxy groups, dihydronaphthyl, tetrahydronaphthyl, fluorenyl, anthryl or phenanthryl, preferably
- the heterocyclic group may be, for example, a group having one or two nitrogen atoms in the ring such as a pyrrolidinyl, imidazolyl, imidazolidinyl, piperidyl or piperazinyl group, the group having two nitrogen atoms in the ring being optionally substituted on the second nitrogen atom by a Cj-C 4 -alkyl, hydroxy- -C -alkyl, C r C 4 -alkylcarbonyl, a C C 4 -alkoxycarbonyl or phenyl- -C 4 -alkyl group, or the heterocyclic group may be a group having one nitrogen atom and one oxygen atom in the ring, such as a tetrahydro-oxazolyl, tetrahydro-isoxazolyl or mopholin
- Preferred compounds of formula I and their salts are compounds of formula
- R 1 is as hereinbefore and, when it is a group of formula ⁇ , it is a group of formula
- R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are as hereinbefore defined.
- R 1 is a - o-alkyl, especially C C 4 -alkyl, C 2 - 0 - alkenyl, especially C 2 -C 4 -alkenyl, C 3 - o-cycloalkyl, especially C 3 -C 6 -cycloalkyl, benzo-C 3 - Cr ⁇ -cycloalkyl, especially benzo-C 5 -C6-cycloalkyl, phenyl- - o-alkyl, especially phenyl- - C 4 -alkyl, or C 3 -Cio-cycloalkyl-C r C 4 -alkyl, especially C 3 -C 6 -cycloalkyl-C ⁇ -C 4 -alkyl, group which is optionally substituted by a hydroxy, carboxy or -C 4 -alkoxycarbonyl group, or R 1 is a heterocyclyl radical having 5 or 6 ring atom
- R 1 is a group of formula II or formula TV respectively in which one of R 6 , R 7 and R 8 is hydrogen, -C 4 -alkyl or C r C 4 -alkoxy, and (i) the second and third of R 6 , R 7 and R 8 are each independently hydrogen, C C 4 -alkyl or -C 4 -alkoxy or (ii) the second of R 6 , R 7 and R 8 is hydrogen and the third of R 6 , R 7 and R 8 is carboxy, C C 10 -, preferably C r C 4 - alkoxycarbonyl, carboxy C r C ⁇ 0 -, preferably carboxy-C r C 4 -alkyl, -Cio-alkoxycarbonyl- - o-alkyl, preferably C r C 4 -alkoxycarbonyl-C r C 4 -alkyl, -N(R 9 )R 10 , -SO 2 N(R 11 )R 12 , C
- R 9 is hydrogen or -Cio-, preferably C r C 4 -, alkyl and R 10 is hydrogen, - o-, preferably C C -, alkyl, or -COR 15 where R 15 is Ci- o-, preferably Cj-C 4 -, alkyl, -Cjo-haloalkyl, preferably Cj-C 4 -haloalkyl, Cj-Cio-alkoxy-CrCio-alkyl, preferably C ⁇ -C 4 -alkoxy- -C - alkyl, Cj- o-alkoxycarbonyl, preferably -C 4 -alkoxycarbonyl, carboxy-Cy- o-alkyl, preferably carboxy-C r C 4 -alkyl, or CrC ⁇ o-alkoxycarbonyl-C r C ⁇ 0 alkyl, preferably -C 4 - alkoxycarbonyl- -C 4 -alkyl, or
- Preferred compounds of formula I or m and their salts include those in which:
- X is a group NR 5 ,
- R 1 is a C C 4 -alkyl, C 2 -C 4 -alkenyl, C 3 -C 5 cycloalkyl, benzo-C 5 -C ⁇ rcycloalkyl, phenyl- -C 4 - alkyl or C 3 -C 5 cycloalkyl- -C 4 -alkyl group, which is optionally substituted by a hydroxy, carboxy or C
- R 9 is hydrogen or -C 4 alkyl and R 10 is hydrogen, C C 4 alkyl, or -COR 15 where R 15 is - C 4 -alkyl, C C 4 -haloalkyl, C C 4 -alkoxy, CrC 4 -alkoxy-C C 4 alkyl, C r C 4 -alkoxycarbonyl, or Cj-C 4 -alkoxycarbonyl-C ⁇ -C 4 -alkyl, or R 9 and R 10 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 or 6 ring atoms including one or two ring nitrogen atoms, or one nitrogen ring atom and one oxygen ring atom, R 11 is hydrogen or C ⁇ -C 4 -alkyl and R 12 is hydrogen, -C 4 -alkyl, hydroxy- - -alkyl, - C 4 -alkoxy- C C 4 -alkyl or C C 4 -alkoxycarbonyl-
- R 1 is -C 4 -alkyl which is optionally substituted by hydroxy, C 2 -C 4 -alkenyl, Q-Q- cycloalkyl which is optionally substituted by carboxy or Q-C 4 -alkoxycarbonyl, benzo-Q- Q-cycloalkyl, phenyl-C r C 4 -alkyl optionally substituted by hydroxy, Q-Q-cycloalkyl- Q- C 4 -alkyl, a heterocyclyl radical having 6 ring atoms and one or two nitrogen atoms in the ring optionally substituted on a ring nitrogen atom by phenyl- -C 4 -alkyl, or a group of formula TV in which one of R 6 , R 7 and R 8 is hydrogen, -C 4 -alkyl or -C -alkoxy, and (i) the second and third of R 6 ,
- R 1 is Q-Q-alkyl or Q-Q 0 cycloalkyl
- one of R 2 , R 3 and R 4 is hydrogen
- either (i) the second of R 2 , R 3 and R 4 is hydrogen and the third of R 2 , R 3 and R 4 is carboxy, Q-Q-alkoxycarbonyl or -N(R 9 )R 10
- R 9 and R 10 together with the attached nitrogen atom denote a heterocyclic group having 5 or 6 ring atoms including two ring nitrogen atoms or one ring nitrogen atom and one ring oxygen atom
- the second and third of R 2 , R 3 and R 4 are attached to adjacent carbon atoms on the indicated benzene ring and together with the carbon atoms to which they are attached denote a heterocyclic group having 5 or 6 ring atoms, of which one or two are nitrogen atoms.
- R 1 is Q-Q-alkyl or Q-Q-cycloalkyl
- one of R 2 , R 3 and R 4 is hydrogen and either (a) the second of R 2 , R 3 and R 4 is hydrogen and the third of R 2 , R 3 and R 4 is carboxy, Q-Q-alkoxycarbonyl or -N(R 9 )R 10 where R 9 and R 10 together with the attached nitrogen atom denote a heterocyclic group having 6 ring atoms including one ring nitrogen atom and one ring oxygen atom, or (b) the second and third of R 2 , R 3 and R 4 are attached to adjacent carbon atoms on the indicated benzene ring and denote, together with said adjacent carbon atoms, a heterocyclic group having 5 ring atoms, of which two are nitrogen atoms.
- Another group of preferred compounds of formula I or HI and their salts are those where X is a sulfur atom, R 1 is Q-Q-alkyl, two of R 2 , R 3 and R 4 are hydrogen and the third of R 2 , R 3 and R 4 is carboxy, Q-Q-alkoxycarbonyl, or -N(R 9 )R 10 where R 9 is hydrogen or Q-Q- alkyl and R 10 is -COR 15 where R 15 is Q-Q-alkyl, or R 9 and R 10 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 or 6 ring atoms including one or two ring nitrogen atoms or one ring nitrogen atom and one ring oxygen atom, preferably a heterocyclic group having 6 ring atoms including one ring nitrogen atom and one ring oxygen atom.
- the compounds represented by formula I are capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts.
- Pharmaceutically acceptable acid addition salts of the compound of formula I include those of inorganic acids, for example, hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p- hydroxybenzoic acid, l-hydroxynaphthalene
- Compounds of formula I which contain acidic, e.g. carboxyl, groups, are also capable of forming salts with bases, in particular pharmaceutically acceptable bases such as those well known in the art; suitable such salts include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared from compounds of formula I by known salt-forming procedures.
- X is NH, R 1 is cyclopropyl, R 2 and R 4 are each hydrogen and R 3 is NHCOOC(CH 3 ) 3 ; or (ii) X is NH, R 1 is cyclopropyl, R 2 and R 4 are each hydrogen and R 3 is morpholino; or (iii) X is NH, R 1 is cyclobutyl, R 2 and R 4 are each hydrogen and R 3 is 4-tert- butoxycarbonyl-1 -piperazinyl; or
- X is NH, R 1 is cyclobutyl, R 2 and R 4 are each hydrogen and R 3 is -N(CH 3 )COCH 3 ; or (v) X is NH, R 1 is isopropyl, R 2 and R 4 are each hydrogen and R 3 is -SO 2 N(CH 3 ) 2 ; or (vi) X is NH, R 1 is cyclopropyl, R 2 and R 4 are each hydrogen and R 3 is 4-acetyl-l- piperazinyl; or
- X is NH, R 1 is tert-butyl, R 2 is hydrogen and R 3 and R 4 together denote -CH 2 -O-CO-; or
- X is O, R 1 is cyclobutyl, R 2 and R 4 are each hydrogen and R 3 is -N(CH 3 )COCH 3 ; or (ix) X is NH, R 1 is cyclopropyl, R 2 and R 4 are each hydrogen and R 3 is 4-methyl-l- piperazinyl; or
- (x) X is NH, R 1 is tert-butyl, R 2 and R 4 are each hydrogen and R 3 is -N(CH 3 )COCH 3 ; or (xi) X is NH, R 1 is isopropyl, R 2 and R 4 are each hydrogen and R 3 is -N(CH 2 CH 3 )COCH 3 ; or
- X is NH, R 1 is cyclopropyl, R 2 and R 4 are each hydrogen and R 3 is -
- N(CH 3 )COCH 2 CH 3 the compounds being in free form or in the form of pharmaceutically acceptable salts, particularly hydrochloride or trifluoroacetate salts.
- the present invention also provides a process for the preparation of compounds of formula I and their salts which comprises
- X, R 1 , R 2 , R 3 and R 4 are as hereinbefore defined and Y is a leaving group, preferably halogen such as bromine, iodine or, in particular chlorine, a free functional group in the compounds of formulae V and VI other that those involved in the reaction being protected, if necessary, by a removable protecting group; or
- R 1 is as hereinbefore defined and R 2 a , R 3 a and R 4 a are respectively the same as R 2 , R 3 and R 4 as hereinbefore defined, with the exception that at least one of them is a group of formula -SO 2 -Hal, where Hal is halogen, preferably chlorine or bromine; or
- Process variant (A) can be carried out using conventional procedures. It is conveniently, carried out in an inert organic solvent, preferably a polar solvent such as dioxan or N- methylpyrrolidone.
- the reaction temperature is conveniently from 50 to 250°C, preferably from 100 to 150°Q
- the reaction may be catalysed by a strong acid, a tertiary base or, preferably, metal ions such as Ag, Cu, Li, Ni, Zn, La, Yb or Sn.
- the reaction is conveniently carried out using 1 to 5 equivalents, for example 1 to 3 equivalents, of the compound of formula VI, per equivalent of the compound of formula V.
- Process variant (B) may be carried out by conventional methods for ester cleavage, for example using conventional acid- or base- catalysed hydrolysis, or analogously as described hereinafter in the Examples.
- Process variant (C) may be effected using conventional esterification procedures or analogously as described hereinafter in the Examples.
- Process variant (D) may be effected by conventional procedures, for example by reaction of the halosulfonyl compound of formula VTJ with a compound of formula HN(R ⁇ )R 12 where R 11 and R 12 are as hereinbefore defined under known conditions or analogously as described hereinafter in the Examples.
- Compounds of formula VH are known or may be prepared by methods analogous to those used for the preparation of known compounds, for example by reacting a corresponding compound, which is unsubstituted in the position on the benzene ring where the halosulfonyl group is to be introduced, with a halosulfonating agent such as chlorosulfonic acid, e.g. as described hereinafter in the Examples.
- Process variant (E) may be effected by conventional methods, for example by conversion of the corresponding carboxy compound into an acid halide and reacting the acid halide with a compound of formula HN(R B )R 14 where R 13 and R 14 are as hereinbefore defined under known conditions or analogously as described hereinafter in the Examples.
- Compounds of formula I in free form may be converted into salt form, and vice versa, in a conventional manner.
- the compounds in free or salt form can be obtained in the form of hydrates or solvates containing a solvent used for crystallization.
- compositions of formula I in free or salt form are useful as pharmaceuticals. Accordingly the invention also provides a compound of formula I in free or pharmaceutically acceptable salt form for use as a pharmaceutical.
- the compounds of formula I in free or pharmaceutically acceptable salt form hereinafter referred to alternatively as "agents of the invention", inhibit the activity of the tyrosine protein kinase syk, which is an activator of pro-inflammatory cells driving an allergic response. This inhibitory property of the agents of the invention can be demonstrated in the following assay:
- the effect of an agent of the invention on the phosphorylation of a peptide by syk kinase is determined.
- the phosphate is transferred from the terminal phosphate of adenosine triphosphate (ATP) to the biotin-modified peptide biotin-EDPDYEWPSA (available from Genosys) which is a known specific substrate for syk.
- biotin-EDPDYEWPSA available from Genosys
- 33 P- phosphorylated peptide binds to streptavidin-polyvinyltoluene (PVT) Scintillation Proximity Assay (SPA) beads (available from Amersham), the emitted ⁇ -particles excite the fluorophore in the beads and produce light.
- PVT streptavidin-polyvinyltoluene
- SPA Scintillation Proximity Assay
- Optiplate (Canberra Packard) are added (i) the compound under test in DMSO/distilled water (lO ⁇ l), (ii) 20 ⁇ l of a composition formed by mixing ImM biotin- EDPDYEWPSA (5.5 ⁇ l), 300 ⁇ M ATP (18.3 ⁇ l), and 33 P-ATP in sufficient amount to add O.l ⁇ Ci 33 P-ATP per well (l.l ⁇ l on the day of production) and making up the volume to 2.2ml with a buffer (Buffer A) prepared by dissolving tris-base (0.36g) in distilled water (80ml), adjusting the pH to 7.5 with 1M hydrochloric acid, adding 1M aqueous MgCl 2 (1.5ml), 50mM aqueous sodium orthovanadate (30 ⁇ l) and 1M aqueous dithiothrietol (150 ⁇ l), and making the volume up to 120 ml with distilled water, (iii) 0.5% w/v sy
- the plate is incubated at room temperature for 30 minutes with shaking, the reaction is then terminated by addition to all wells of 150 ⁇ l of a mixture prepared by reconstituting 500mg Streptavidin-PVT SPA beads in 373 ml of Tris-buffered saline containing 673.6g cesium chloride, 20ml 0.5M EDTA and 27.5mg ATP (disodium salt) per litre.
- the plate is again incubated at room temperature for 30 minutes with shaking, then sealed using Top Seal-S (Canberra Packard) according to the manufacturer's insturctions and left to stand at room temperature for 1 hour.
- Top Seal-S Canberra Packard
- test compound selected to cover the range of 0% to 100% inhibition and the concentration at which 50% inhibition of syk kinase phosphorylation occurs (IQ 0 ) for each compound is determined from concentration- inhibition curves in a conventional manner.
- the compounds of the Examples hereinbelow have IC 50 values of the order of l ⁇ M or less in the above assay.
- the compounds of Examples 1 to 7 hereinbelow have IC 50 values of 3nM, 4nM, 5nM, 5nM, 9nM, lOnM and lOnM respectively
- the compounds of Examples 102 to 104 have IQo values of 5nM, 2nM and 3.6nM respectively
- the compunds of Examples 138, 141, 170, 172, 188 and 201 have IQ 0 values of 14nM, 4.5nM, lOnM, 6nM, 5nM and 5nM respectively.
- the agents of the invention are useful in the treatment of conditions which are mediated by syk kinase, particularly inflammatory or allergic conditions. Treatment in accordance with the invention may be symptomatic or prophylactic.
- the agents of the invention are useful in the treatment of inflammatory or obstructive airways diseases.
- Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma.
- Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "whez infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics.
- Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti- inflammatory (e.g. corticosteroid) or bronchodilatory. Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping".
- “Morning dipping” is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
- inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary or airways disease (COPD or COAD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy.
- ARDS adult respiratory distress syndrome
- COAD or COAD chronic obstructive pulmonary or airways disease
- chronic bronchitis or dyspnea associated therewith emphysema
- exacerbation of airways hyperreactivity consequent to other drug therapy in particular other inhaled drug therapy.
- the invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
- pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
- pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
- aluminosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
- aluminosis anthracosis
- asbestosis chalicosis
- ptilosis ptilosis
- siderosis silicosis
- tabacosis tabacosis and byssinosis.
- agents of the invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g.
- eosinophilic infiltration of pulmonary tissues including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil- related disorders of the airways consequential or concomitant to L ⁇ ffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg- Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
- Agents of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
- Agents of the invention may also be used for the treatment of other diseases or conditions, in particular diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory bowel disease such as ulcerative colitis and Crohn's disease.
- diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis
- diseases affecting the nose including allergic rhinitis, and inflammatory bowel disease such as ulcerative colitis and Crohn's disease.
- an agent of the invention in inhibiting inflammatory conditions, for example in inflammatory airways diseases, may be demonstrated in an animal model, e.g. a mouse or rat model, of airways inflammation or other inflammatory conditions, for example as described by Szarka et al, J. Immunol. Methods (1997) 202:49-57; Renzi et al, Am. Rev. Respir. Dis. (1993) 148:932-939; Tsuyuki et al., J. Clin. Invest. (1995) 96:2924- 2931; and Cernadas et al (1999) Am. J. Respir. Cell Mol. Biol. 20:1-8.
- the agents of the invention are also useful as co-therapeutic agents for use in conjunction with anti-inflammatory or bronchodilatory drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
- An agent of the invention may be mixed with the anti-inflammatory or bronchodilatory drug in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the anti-inflammatory or bronchodilatory drug.
- Such anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone, fluticasone or mometasone, and dopamine receptor agonists such as cabergoline, bromocriptine or ropinirole.
- bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular ipratropium bromide, oxitropium bromide and tiotropium bromide.
- Combinations of agents of the invention and steroids may be used, for example, in the treatment of COPD or, particularly, asthma.
- Combinations of agents of the invention and anticholinergic or antimuscarinic agents or dopamine receptor agonists may be used, for example, in the treatment of asthma or, particularly, COPD.
- the invention also provides a method for the treatment of a condition mediated by syk kinase, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease, which comprises administering to a subject, particularly a human subject, in need thereof an effective amount of a compound of formula I in a free or pharmaceutically acceptable salt form as hereinbefore described.
- the invention provides a compound of formula I, in free or pharmaceutically acceptable salt form, as hereinbefore described for use in the manufacture of a medicament for the treatment of a condition mediated by syk kinase.
- the agents of the invention may be administered by any appropriate route, e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
- any appropriate route e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I in free or pharmaceutically acceptable salt form together with a pharmaceutically acceptable diluent or carrier therefor.
- the composition may contain a co-therapeutic agent such as an anti-inflammatory or bronchodilatory drug as hereinbefore described.
- Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art.
- oral dosage forms may include tablets and capsules.
- Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g. patches.
- Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations.
- the invention includes (A) an agent of the invention in inhalable form, e.g. in an aerosol or other atomisable composition or in inhalable paniculate, e.g. micronised form, (B) an inhalable medicament comprising an agent of the invention in inhalable form; (C) a pharmaceutical product comprising such an agent of the invention in inhalable form in association with an inhalation device; and (D) an inhalation device containing an agent of the invention in inhalable form.
- Dosages of agents of the invention employed in practising the present invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for administration by inhalation are of the order of 0.1 to 100 mg/kg while for oral administration suitable daily doses are of the order of 1 to 1000 mg/kg.
- Meta-(3,5-dimethylmorpholino) aniline a. Meta-(3,5-dimethylmorpholino) nitrobenzene. l-Fluoro-3-nitrobenzene (2.8g, 0.02M) and 2,6-dimethylmorpholine (12.5g, 0.12M) are heated in DMSO(33ml) at 100°C for 66 hours. The cooled mixture is poured into water (300ml). The precipitate is collected by filtration, washed with water and dried under vacuum; ES+ (M+Na) 258.96; mp 126.6-127.8°Q
- Meta-(3,5-dimethylmorpholino) nitrobenzene (la) (2g, 8.5mmol) is hydrogenated in ethanol (50ml), over 10%Pd on carbon (200mg) for 1.5 hours.
- the catalyst is removed by filtration and the solvent removed evaporation to yield an oil.
- the enantiomers can be separated by silica column chromatography. ES+ (M+l) 207.36.
- Meta-morpholino nitrobenzene (2a) (2g, 9.6mmol) is hydrogenated in a mixture of ethanol and ethyl acetate (50ml/10ml), over 10% Pd on carbon (200mg) for 1 hour.
- the catalyst is removed by filtration and the solvent removed by evaporation to yield a solid, which is dried under vacuum; ES+ (M+l) 179.35; mp 125.4-127.6°Q 3.
- Meta-(l-methylpiperazine) nitrobenzene (3a) (2g, 0.009M) is hydrogenated in ethanol (50ml), over 10%Pd on carbon (lOOmg) for 0.5 hours.
- the catalyst is removed by filtration and the solvent removed by evaporation to yield an oil; ES+ (M+l) 191.5; mp.87.6-89.0°Q
- Para-(l-methylpiperazine) aniline a. Para-(l-methylpiperazine) nitrobenzene l-Fluoro-4-nitrobenzene (8.5ml, 0.08M) and 1-methyl piperazine (22.5ml, 0.247M) are heated in DMSO(lOOml) at 100°C for 60 hours. The cooled mixture is poured into water (500ml) and the precipitate collected by filtration, washed with water and dried under vacuum; ES+ (M+l) 222; mp 57.4-58.9°C.
- N-acetyl-N-ethyl-4-nitroaniline (9a) (1.8g, 8.64mmol) is hydrogenated in THF (30ml), over 10%Pd on carbon (lOOmg) for 1.5 hours.
- the catalyst is removed by filtration and the solvent removed evaporation.
- the product crystalises on standing in hexane, and following filtration, is dried under vacuum; ES+ (M+l) 178.88.
- N-propionyl-N-methyl -4-aminoaniline a. N-propionyl-N-methyl-4-nitroaniline.
- N-Methyl cyclopropylamine a. N-Carbobenzyloxy cyclopropylamine
- N-carbobenzyloxy cyclopropylamine is carried out according to the method outlined in J. Heterocycl. Chem (1983), 1035, using carbobenzyloxychloride (56.3g, 0.33M), cyclopropylamine (19.6g, 0.344M), sodium carbonate (36. lg, 0.34M) in toluene (400ml) and water (400ml).
- carbobenzyloxychloride 56.3g, 0.33M
- cyclopropylamine (19.6g, 0.344M
- sodium carbonate 36. lg, 0.34M
- toluene 400ml
- water 400ml
- N-carbobenzyloxy cyclopropylamine is carried out according to the method outlined in J. Heterocycl. Chem (1983), 1035, using N-carbobenzyloxy cyclopropylamine (14a)(10.5g, 0.055M) in DMF (80ml), sodium hydride(1.4g) and methyl iodide (4ml). The product is purified by vacuum distillation. Bp 86-92°C, 0.02 Torr. c. N-Methyl cyclopropylamine
- N-methyl cyclopropylamine is carried out according to the method outlined in J. Heterocycl. Chem (1983), 1035, using N-methyl-N-carbobenzyloxy cyclopropylamine(14b)(11.45g, 0.055M), concentrated hydrochloric acid(4.32ml), 10%Pd on carbon (700mg) in ethanol( 135ml). The product is obtained and used as an ethereal solution.
- Para-(l-ethylpiperazine) aniline a. Para-(l-ethylpiperazine) nitrobenzene l-Fluoro-4-nitrobenzene (0.54ml, 0.005M), 1-ethyl piperazine (1.9ml, 0.015M) and potassium carbonate (0.69g, 0.005M) are heated in acetonitrile (7ml) at 85°C under N 2 for 24 hours. The cooled mixture is partitioned between dichloromethane and water. The organic layer is separated and the aqueous extracted twice with dichloromethane.
- Para-(l-ethylpiperazine) nitrobenzene (0.5g, 0.002M) is hydrogenated in ethanol/ethyl acetate mixture (12.5ml/2.5ml), over 10% Pd on carbon (50mg) for 24 hours.
- the catalyst is removed by filtration and the solvent removed by evaporation to yield a solid which is dried under vaccum.
- Para-(l-hydroxypiperidine) aniline (19(b)) is prepared analogously to 15(b) from 19(a); TOF ES+(M+ 1)193.
- Method A The corresponding 2-chloro-6-substituted purine of formula V is heated with 1.5 to 3 equivalents of the appropriate aniline of formula VI at temperatures between 90 and 190°C for times between 3 and 78 hours.
- the required product is isolated by (i) precipitation from the reaction mixture, washing with methanol, ethanol, water or dioxan and optionally isolation of a hydrochloride salt by treatment with HC1 in dioxan or (ii) concentration from methanol or ethanol or (iii) concentration followed by flash silica chromatopgraphy or direct purification by preparative HPLQ
- Method B As Method A, except that the purine of formula V is heated with 1.5 equivalents of the aniline of formula VI and 1.5 equivalents of diisopropylethylamine at 130°C for 16-96 hours and the product is isolated by partitioning between ethyl acetate and water, followed by extraction with ethyl acetate, concentration and purification by flash silica chromatography.
- Method C As Method A, except that the reaction mixture is partitioned between ethyl acetate and water, basified with IN NaOH or saturated aqueous NaHCO 3 , extracted with ethyl acetate, concentrated and purified by flash silica chromatography.
- Method D The corresponding ester in ethanol, THF/aqueous methanol or THF/water is treated with 2.5 to 13 equivalents of IN NaOH or LiOH at room temperature. The mixture is neutralised with IN hydrochloric acid and solvent removed. The product is isolated by dissolution in ethanol, filtration and evaporation of the filtrate.
- Method E As method A, with the addition of concentrated hydrochloric acid or trifluoroacetic acid to the heated reaction mixture.
- Method F As Method A, followed by treatment of the product with chlorosulfonic acid. 400 ⁇ L of a solution of the resulting sulfonyl chloride is added to a 1M solution of the appropriate amine of formula HN(R 11 )R 12 and, after 2 hours, the solvent is removed and the product purified by preparative HPLC.
- Method G As Method A, with the addition of silver triflate (1 equivalent) to the heated reaction mixture.
- Method H The corresponding carboxylic acid is stirred in DMF, with 1 equivalent of the appropriate amine of formula HN(R 13 )R 14 dissolved in THF, and equivalent amounts of N- dimethylaminopyridine and benzotriazol- 1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate at 20°C for 16 hours.
- the product is isolated by precipitation from the reaction mixture on treatment with IN hydrochloric acid, followed by purification by flash silica chromatography.
- Method I The corresponding carboxylic acid is reacted with excess thionyl chloride to give the corresponding acid chloride, which is treated with the appropriate amine of formula HN(R U )R 14 ), or appropriate alcohol, in benzene.
- the product is isolated by evaporation, and purified by preparative HPLC.
- Method J The corresponding 2-chloro-6-substituted purine of formula V and the appropriate aniline of formula VI (2.2 equivalents) are microwaved at 140°C, 50% power, for 10 minutes, followed by trituration with methanol. The product is isolated by filtration.
- the prepared compounds of formula HI designated Examples 1 to 221, are shown in the table below, together with the general method used. In the table, CyPr denotes cyclopropyl, CyBu denotes cyclobutyl, CyPe denotes cyclopentyl and BnPp denotes N- benzylpiperidyl.
- 6-Cyclobutylamino-2-anilinopurine (200mg, 0.631mmol) is added cautiously to chlorosulfonic acid (2ml). The solution is stired at 50°C, for 2 hours. After cooling to ambient temperature, the mixture is added dropwise to ice/water(20ml). The precipitate is filtered and washed with cold water (5ml). The solid, 6-cyclobutylamino-2-(4- chlorosulfonylanilino)purine, is dissolved in NMP (2ml).
- the product is crystallised from methanol to give 6-ethylamino-2- (methyl-4-aminobenzoate)purine; ES+ (M+l) 312.84; mp 229-230°Q c.
- a suspension of 6-ethylamino-2-(methyl-4-aminobenzoate)purine (0.7g, 2mmol) in THF/water(l:l)(55ml)
- a solution of lithium hydroxide monohydrate l.lg, 26mmol
- the mixture is stirred at 55°C for 48 hours.
- the solvent is removed by evaporation and the residue ultrasonicated in water.
- the solid is removed by filtration and the filtrate neutralised with cone, hydrochloric acid.
- the precipitate is isolated by filtration, washed with water and dried under vacuum, at 75°C; ES+ (M+l) 398.71; mp 301-303°C dec.
- Sodium metal (1.53g, 0.067M) is dissolved in a mixture of cyclobutanol (8g, 0.11M) and dry THF (20ml), at 90°C, under nitrogen, for 4 hours. The mixture is cooled to 0°C and 2,6-dichloropurine (4.39g, 0.024M) added. The mixture is stirred at ambient temperature for 0.5 hours, prior to the addition of glacial acetic acid (10ml) and water (30ml).
- Example 6 The product of Example 6 (500mg, 1.42 mmol) is slurried in a mixture of dichloromethane (5ml) and water (5ml). Aqueous 4N sodium hydroxide is added to adjust the aqueous layer to pH 10. The organic layer is discarded and the aqueous layer is extracted with ethyl acetate. The solvent is removed to give a solid which is slurried in dichloromethane, filtered and dried; to yield a colourless solid.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60005684T DE60005684T2 (en) | 1999-07-30 | 2000-07-28 | PURIN DERIVATIVE INHIBITORS OF TYROSI PROTEIN KINASE SYK |
SK126-2002A SK285730B6 (en) | 1999-07-30 | 2000-07-28 | Purine derivatives, process for preparation thereof, pharmaceutical composition comprising the same and their use |
CA002379560A CA2379560C (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk |
EP00953112A EP1200435B1 (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk |
NZ516667A NZ516667A (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk |
JP2001514337A JP2003506375A (en) | 1999-07-30 | 2000-07-28 | Purine derivative inhibitors of tyrosine protein kinase SYK |
PL00354477A PL354477A1 (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk |
AT00953112T ATE251160T1 (en) | 1999-07-30 | 2000-07-28 | PURINE DERIVATIVE INHIBITORS OF TYROSI-PROTEIN KINASE SYK |
IL14745500A IL147455A0 (en) | 1999-07-30 | 2000-07-28 | Purine derivative inhibitors of tyrosine protein kinase syk |
AU65677/00A AU767349B2 (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk |
BR0012888-0A BR0012888A (en) | 1999-07-30 | 2000-07-28 | Protein tyrosine sic kinase purine derived inhibitors |
MXPA02001102A MXPA02001102A (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk. |
DK00953112T DK1200435T3 (en) | 1999-07-30 | 2000-07-28 | Purine derivative inhibitors of tyrosine protein kinase SYK |
US10/048,577 US6589950B1 (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase SYK |
NO20020467A NO20020467L (en) | 1999-07-30 | 2002-01-29 | Purine derivative inhibitors of tyrosine protein kinase ill |
HK02107013.6A HK1046679A1 (en) | 1999-07-30 | 2002-09-25 | Purine derivatives inhibitors of tyrosine protein kinase syk |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9918035.8 | 1999-07-30 | ||
GBGB9918035.8A GB9918035D0 (en) | 1999-07-30 | 1999-07-30 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001009134A1 true WO2001009134A1 (en) | 2001-02-08 |
Family
ID=10858317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/007311 WO2001009134A1 (en) | 1999-07-30 | 2000-07-28 | Purine derivatives inhibitors of tyrosine protein kinase syk |
Country Status (33)
Country | Link |
---|---|
US (1) | US6589950B1 (en) |
EP (1) | EP1200435B1 (en) |
JP (2) | JP2003506375A (en) |
KR (1) | KR100485289B1 (en) |
CN (1) | CN1213047C (en) |
AR (1) | AR029175A1 (en) |
AT (1) | ATE251160T1 (en) |
AU (1) | AU767349B2 (en) |
BR (1) | BR0012888A (en) |
CA (1) | CA2379560C (en) |
CO (1) | CO5180626A1 (en) |
CZ (1) | CZ2002299A3 (en) |
DE (1) | DE60005684T2 (en) |
DK (1) | DK1200435T3 (en) |
EC (1) | ECSP003589A (en) |
ES (1) | ES2208395T3 (en) |
GB (1) | GB9918035D0 (en) |
HK (1) | HK1046679A1 (en) |
HU (1) | HUP0201935A3 (en) |
IL (1) | IL147455A0 (en) |
MX (1) | MXPA02001102A (en) |
MY (1) | MY126862A (en) |
NO (1) | NO20020467L (en) |
NZ (1) | NZ516667A (en) |
PE (1) | PE20010543A1 (en) |
PL (1) | PL354477A1 (en) |
PT (1) | PT1200435E (en) |
RU (1) | RU2248977C2 (en) |
SK (1) | SK285730B6 (en) |
TR (1) | TR200200234T2 (en) |
TW (2) | TWI274754B (en) |
WO (1) | WO2001009134A1 (en) |
ZA (1) | ZA200200783B (en) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001041724A2 (en) * | 1999-12-08 | 2001-06-14 | L'oreal | Compositions for dyeing keratinic fibres, containing paraphenylenediamine derivatives with an azetidinyl group |
WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
WO2003057695A1 (en) * | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
EP1444982A1 (en) * | 2003-02-06 | 2004-08-11 | Merckle Gmbh | The use of purine derivatives as selective kinase inhibitors |
WO2005028479A2 (en) * | 2003-09-25 | 2005-03-31 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting purine derivatives |
US6897307B2 (en) | 2002-03-28 | 2005-05-24 | Novartis Ag | Process for preparing 2,6-diaminopurine derivatives |
WO2005047524A2 (en) | 2003-11-10 | 2005-05-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
JP2005523251A (en) * | 2002-01-10 | 2005-08-04 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Rho-kinase inhibitor |
US6943172B2 (en) | 2002-01-23 | 2005-09-13 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2005097135A2 (en) * | 2004-04-05 | 2005-10-20 | Novartis Ag | Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives |
EP1656378A2 (en) * | 2003-08-15 | 2006-05-17 | Irm Llc | Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
WO2006004636A3 (en) * | 2004-06-28 | 2006-05-26 | Bristol Myers Squibb Co | Fused heterocyclic kinase inhibitors |
WO2007042298A1 (en) * | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
US7329672B2 (en) | 2002-02-01 | 2008-02-12 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
EP1897882A1 (en) * | 2005-06-16 | 2008-03-12 | Zhe Jiang Medecine Co., Ltd. Xinchang Pharmaceutical Factory | N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
WO2008081928A1 (en) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Pyrazolopyrimidine compound |
WO2008107444A1 (en) | 2007-03-07 | 2008-09-12 | Boehringer Ingelheim International Gmbh | 9h- purine derivatives and their use in the treatment of proliferative diseases |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
WO2009026107A1 (en) * | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7547702B2 (en) | 2000-09-20 | 2009-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | 4-amino-quinazolines |
US7579471B2 (en) | 2002-04-08 | 2009-08-25 | Pfizer, Inc. | Tropane derivatives useful in therapy |
US7601713B2 (en) | 2005-12-15 | 2009-10-13 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
FR2929851A1 (en) * | 2008-04-09 | 2009-10-16 | Centre Nat Rech Scient | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE TYROSINE KINASE SYK PROTEIN AND METHOD OF IDENTIFYING SAID MOLECULES |
WO2009131687A2 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US7655802B2 (en) * | 2002-07-19 | 2010-02-02 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
US7851480B2 (en) | 2004-11-24 | 2010-12-14 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
WO2011079051A1 (en) | 2009-12-23 | 2011-06-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2010111406A3 (en) * | 2009-03-24 | 2011-07-07 | Myriad Pharmaceuticals, Inc. | Purine derivatives useful as anti - cancer agents |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
US8501944B2 (en) | 2008-04-16 | 2013-08-06 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8664223B2 (en) | 2006-01-19 | 2014-03-04 | Janssen Pharmaceutica N.V | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8916554B2 (en) | 2002-03-13 | 2014-12-23 | Janssen Pharmaceutica, N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
US8952027B2 (en) | 2008-04-16 | 2015-02-10 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US8957081B2 (en) | 2006-12-08 | 2015-02-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US9012462B2 (en) | 2008-05-21 | 2015-04-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9150543B2 (en) | 2004-07-28 | 2015-10-06 | Janssen Pharmaceutica N. V. | Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9353115B2 (en) | 2011-06-01 | 2016-05-31 | Janus Biotherapeutics, Inc. | Immune system modulators |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
EP3040337A4 (en) * | 2013-08-30 | 2017-01-18 | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
EP3256475A4 (en) * | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
WO2019076817A1 (en) | 2017-10-19 | 2019-04-25 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
WO2019241896A1 (en) * | 2018-06-22 | 2019-12-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
US10711002B2 (en) | 2016-04-21 | 2020-07-14 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001040800A2 (en) * | 1999-11-30 | 2001-06-07 | Parker Hughes Institute | Syk localized at centrosome |
GB0101686D0 (en) * | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
EP1578722A4 (en) * | 2001-10-12 | 2006-09-06 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
MXPA04007776A (en) | 2002-03-13 | 2004-10-15 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase. |
US20060252943A1 (en) * | 2002-06-17 | 2006-11-09 | Amogh Boloor | Chemical process |
ZA200603719B (en) * | 2003-11-06 | 2007-09-26 | Celgene Corp | Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders |
US8057815B2 (en) * | 2004-04-19 | 2011-11-15 | Portola Pharmaceuticals, Inc. | Methods of treatment with Syk inhibitors |
WO2005118543A1 (en) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | Kinase inhibitor and use thereof |
US7452993B2 (en) | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7709645B2 (en) * | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
MX2007001127A (en) * | 2004-07-27 | 2007-07-11 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators. |
JP2008512428A (en) * | 2004-09-10 | 2008-04-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of ciclesonide and Syk inhibitor and method of use thereof |
CA2628474A1 (en) * | 2005-11-03 | 2007-05-10 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
JP5225104B2 (en) * | 2006-01-19 | 2013-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Aminophenyl derivatives as new inhibitors of histone deacetylase |
CN101370803B (en) * | 2006-01-19 | 2012-12-12 | 詹森药业有限公司 | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
MX2008012482A (en) * | 2006-03-31 | 2008-10-10 | Abbott Lab | Indazole compounds. |
EP2084162B1 (en) | 2006-10-23 | 2012-09-12 | SGX Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
US20080139531A1 (en) * | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
JP5208123B2 (en) * | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as protein kinase inhibitors |
EP2078020A4 (en) | 2007-04-10 | 2011-10-19 | Sgx Pharmaceuticals Inc | Fused ring heterocycle kinase modulators |
CN101289449A (en) * | 2007-04-20 | 2008-10-22 | 浙江医药股份有限公司新昌制药厂 | 2,6-di-nitrogen-containing substituted purine derivatives, preparation method and applications thereof |
EA200971077A1 (en) * | 2007-05-21 | 2010-04-30 | ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. | HETEROCYCLIC KINASE MODULATORS |
TW200908968A (en) * | 2007-05-29 | 2009-03-01 | Sgx Pharmaceuticals Inc | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
WO2010003084A2 (en) * | 2008-07-02 | 2010-01-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
PE20121480A1 (en) * | 2009-12-17 | 2012-11-10 | Merck Sharp & Dohme | AMINOPYRIMIDINES AS SYK INHIBITORS |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
JP2014513687A (en) | 2011-05-10 | 2014-06-05 | メルク・シャープ・アンド・ドーム・コーポレーション | Pyridylaminopyridine as a Syk inhibitor |
AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
US9216173B2 (en) | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
US9006444B2 (en) | 2011-10-05 | 2015-04-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
AR090650A1 (en) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | TREATMENT FOR INFLAMMATORY RESPONSES INDUCED BY EYE MICROBES |
EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
US9487504B2 (en) | 2012-06-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
EP2863915B1 (en) | 2012-06-22 | 2017-12-06 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
EP2900665B1 (en) | 2012-09-28 | 2018-01-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
WO2014100314A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
EP2988744A4 (en) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
EP2988749B1 (en) | 2013-04-26 | 2019-08-14 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
US9783531B2 (en) | 2013-12-20 | 2017-10-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
EP3116506B1 (en) | 2014-03-13 | 2019-04-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
RU2570113C1 (en) * | 2014-12-08 | 2015-12-10 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | N-(2-acetamidopurin-6-yl)glycine, which has anti-tuberculosis activity |
CA2993288A1 (en) * | 2015-07-24 | 2017-02-02 | Glaxo Group Limited | Treatment for vitiligo |
EP3894392A4 (en) * | 2018-12-11 | 2022-08-24 | Duke University | Compositions and methods for the treatment of cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212535A1 (en) * | 1985-08-17 | 1987-03-04 | Roche Diagnostics GmbH | N6-disubstituted purine derivatives, process for their preparation and medicaments containing them |
WO1993017021A1 (en) * | 1992-02-19 | 1993-09-02 | Pfizer, Inc. | Heterocyclic compounds for enhancing antitumor activity |
WO1993020078A1 (en) * | 1992-04-03 | 1993-10-14 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
WO1995035304A1 (en) * | 1994-06-22 | 1995-12-28 | Macronex, Inc. | Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines |
WO1998005335A1 (en) * | 1996-08-02 | 1998-02-12 | Cv Therapeutics, Inc. | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) |
WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091346B1 (en) * | 1995-11-01 | 2006-08-15 | Novartis Ag | Purine derivatives and processes for their preparation |
GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
-
1999
- 1999-07-30 GB GBGB9918035.8A patent/GB9918035D0/en not_active Ceased
-
2000
- 2000-07-20 TW TW94101835A patent/TWI274754B/en not_active IP Right Cessation
- 2000-07-20 TW TW089114515A patent/TWI255268B/en not_active IP Right Cessation
- 2000-07-25 PE PE2000000744A patent/PE20010543A1/en not_active Application Discontinuation
- 2000-07-26 CO CO00056110A patent/CO5180626A1/en not_active Application Discontinuation
- 2000-07-27 EC EC2000003589A patent/ECSP003589A/en unknown
- 2000-07-27 AR ARP000103890A patent/AR029175A1/en unknown
- 2000-07-28 DK DK00953112T patent/DK1200435T3/en active
- 2000-07-28 JP JP2001514337A patent/JP2003506375A/en not_active Withdrawn
- 2000-07-28 PT PT00953112T patent/PT1200435E/en unknown
- 2000-07-28 KR KR10-2002-7001276A patent/KR100485289B1/en not_active IP Right Cessation
- 2000-07-28 MX MXPA02001102A patent/MXPA02001102A/en active IP Right Grant
- 2000-07-28 BR BR0012888-0A patent/BR0012888A/en not_active Application Discontinuation
- 2000-07-28 CN CNB008110263A patent/CN1213047C/en not_active Expired - Fee Related
- 2000-07-28 AU AU65677/00A patent/AU767349B2/en not_active Ceased
- 2000-07-28 CA CA002379560A patent/CA2379560C/en not_active Expired - Fee Related
- 2000-07-28 WO PCT/EP2000/007311 patent/WO2001009134A1/en not_active Application Discontinuation
- 2000-07-28 EP EP00953112A patent/EP1200435B1/en not_active Expired - Lifetime
- 2000-07-28 CZ CZ2002299A patent/CZ2002299A3/en unknown
- 2000-07-28 TR TR2002/00234T patent/TR200200234T2/en unknown
- 2000-07-28 PL PL00354477A patent/PL354477A1/en not_active Application Discontinuation
- 2000-07-28 IL IL14745500A patent/IL147455A0/en unknown
- 2000-07-28 AT AT00953112T patent/ATE251160T1/en not_active IP Right Cessation
- 2000-07-28 DE DE60005684T patent/DE60005684T2/en not_active Expired - Fee Related
- 2000-07-28 MY MYPI20003444 patent/MY126862A/en unknown
- 2000-07-28 NZ NZ516667A patent/NZ516667A/en unknown
- 2000-07-28 RU RU2002103305/04A patent/RU2248977C2/en not_active IP Right Cessation
- 2000-07-28 HU HU0201935A patent/HUP0201935A3/en unknown
- 2000-07-28 ES ES00953112T patent/ES2208395T3/en not_active Expired - Lifetime
- 2000-07-28 SK SK126-2002A patent/SK285730B6/en not_active IP Right Cessation
- 2000-07-28 US US10/048,577 patent/US6589950B1/en not_active Expired - Lifetime
-
2002
- 2002-01-29 ZA ZA200200783A patent/ZA200200783B/en unknown
- 2002-01-29 NO NO20020467A patent/NO20020467L/en not_active Application Discontinuation
- 2002-09-25 HK HK02107013.6A patent/HK1046679A1/en unknown
-
2007
- 2007-05-16 JP JP2007130684A patent/JP2007217426A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212535A1 (en) * | 1985-08-17 | 1987-03-04 | Roche Diagnostics GmbH | N6-disubstituted purine derivatives, process for their preparation and medicaments containing them |
WO1993017021A1 (en) * | 1992-02-19 | 1993-09-02 | Pfizer, Inc. | Heterocyclic compounds for enhancing antitumor activity |
WO1993020078A1 (en) * | 1992-04-03 | 1993-10-14 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
WO1995035304A1 (en) * | 1994-06-22 | 1995-12-28 | Macronex, Inc. | Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines |
WO1998005335A1 (en) * | 1996-08-02 | 1998-02-12 | Cv Therapeutics, Inc. | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) |
WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
Non-Patent Citations (8)
Title |
---|
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MATSELYUKH, B. P. ET AL: "Analogs of purine bases and purine metabolism in Actinomyces olivaceus", XP002148765, retrieved from STN Database accession no. 81:163864 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TALANIAN, ROBERT ET AL: "DNA polymerase delta: a target for selective inhibitor design", XP002148763, retrieved from STN Database accession no. 113:34419 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TRET'YAKOVA, G. S. ET AL: "Synthesis and study of 2,6-diaminopurines", XP002148766, retrieved from STN Database accession no. 78:16123 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WRIGHT, GEORGE E. ET AL: "Synthesis, cell-growth inhibition, and antitumor screening of 2-(p-butylanilino)purines and their nucleoside analogs", XP002148764, retrieved from STN Database accession no. 106:18980 * |
J. MED. CHEM. (1987), 30(1), 109-16 * |
MIKROBIOL. ZH. (KIEV) (1974), 36(3), 355-7 * |
MOL. ASPECTS CHEMOTHER., PROC. INT. SYMP., 2ND (1990), MEETING DATE 1988, 105-18. EDITOR(S): BOROWSKI, EDWARD;SHUGAR, DAVID. PUBLISHER: PERGAMON, NEW YORK, N. Y. * |
UKR. KHIM. ZH. (RUSS. ED.) (1972), 38(6), 602-5 * |
Cited By (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001041724A3 (en) * | 1999-12-08 | 2001-12-20 | Oreal | Compositions for dyeing keratinic fibres, containing paraphenylenediamine derivatives with an azetidinyl group |
WO2001041724A2 (en) * | 1999-12-08 | 2001-06-14 | L'oreal | Compositions for dyeing keratinic fibres, containing paraphenylenediamine derivatives with an azetidinyl group |
US7547702B2 (en) | 2000-09-20 | 2009-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | 4-amino-quinazolines |
US7858626B2 (en) | 2000-12-21 | 2010-12-28 | Glaxosmithkline Llc | Pyrimidineamines as angiogenesis modulators |
WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
US7262203B2 (en) | 2000-12-21 | 2007-08-28 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
US8114885B2 (en) | 2000-12-21 | 2012-02-14 | Glaxosmithkline Llc | Chemical compounds |
EP2311825A1 (en) * | 2000-12-21 | 2011-04-20 | GlaxoSmithKline LLC | Pyrimidineamines as angiogenesis modulators |
US7105530B2 (en) | 2000-12-21 | 2006-09-12 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
US7705151B2 (en) | 2001-12-21 | 2010-04-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 Naphthridines useful as inhibitors of SYK kinase |
US7678911B2 (en) | 2001-12-21 | 2010-03-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
US7321041B2 (en) | 2001-12-21 | 2008-01-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 Naphthyridines useful as inhibitors of SYK kinase |
WO2003057695A1 (en) * | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
JP2005523251A (en) * | 2002-01-10 | 2005-08-04 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Rho-kinase inhibitor |
US7648986B2 (en) | 2002-01-10 | 2010-01-19 | Bayer Healthcare Llc | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US6943172B2 (en) | 2002-01-23 | 2005-09-13 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US9913842B2 (en) | 2002-02-01 | 2018-03-13 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7655797B2 (en) | 2002-02-01 | 2010-02-02 | Rigel Pharmaceuticals, Inc. | Intermediates for making 2,4-pyrimidinediamine compounds |
US9416112B2 (en) | 2002-02-01 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9346765B2 (en) | 2002-02-01 | 2016-05-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7329672B2 (en) | 2002-02-01 | 2008-02-12 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7329671B2 (en) | 2002-02-01 | 2008-02-12 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7332484B2 (en) | 2002-02-01 | 2008-02-19 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8334296B2 (en) | 2002-02-01 | 2012-12-18 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10709703B2 (en) | 2002-02-01 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8835430B2 (en) | 2002-02-01 | 2014-09-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10682350B2 (en) | 2002-02-01 | 2020-06-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9018204B1 (en) | 2002-02-01 | 2015-04-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7820819B2 (en) | 2002-02-01 | 2010-10-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7803939B2 (en) | 2002-02-01 | 2010-09-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8916554B2 (en) | 2002-03-13 | 2014-12-23 | Janssen Pharmaceutica, N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
US9556161B2 (en) | 2002-03-13 | 2017-01-31 | Janssen Pharmaceutica Nv | Inhibitors of histone deacetylase |
US9150560B2 (en) | 2002-03-13 | 2015-10-06 | Janssen Pharmaceutica Nv | Inhibitors of histone deacetylase |
US9533979B2 (en) | 2002-03-13 | 2017-01-03 | Janssen Pharmaceutica Nv | Amino-derivatives as novel inhibitors of histone deacetylase |
US6897307B2 (en) | 2002-03-28 | 2005-05-24 | Novartis Ag | Process for preparing 2,6-diaminopurine derivatives |
US7579471B2 (en) | 2002-04-08 | 2009-08-25 | Pfizer, Inc. | Tropane derivatives useful in therapy |
US7655802B2 (en) * | 2002-07-19 | 2010-02-02 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7812029B1 (en) | 2002-07-29 | 2010-10-12 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7825116B2 (en) | 2002-07-29 | 2010-11-02 | Rigel Pharmaceuticals, Inc. | N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines |
EP1444982A1 (en) * | 2003-02-06 | 2004-08-11 | Merckle Gmbh | The use of purine derivatives as selective kinase inhibitors |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
US9751893B2 (en) | 2003-07-30 | 2017-09-05 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP1656378A2 (en) * | 2003-08-15 | 2006-05-17 | Irm Llc | Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
EP1656378A4 (en) * | 2003-08-15 | 2011-05-11 | Irm Llc | Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
AU2004274185B2 (en) * | 2003-09-25 | 2009-12-10 | Janssen Pharmaceutica N.V. | HIV replication inhibiting purine derivatives |
US8026245B2 (en) | 2003-09-25 | 2011-09-27 | Janssen Pharmaceutica N.V. | HIV replication inhibiting purine derivatives |
WO2005028479A3 (en) * | 2003-09-25 | 2005-06-16 | Janssen Pharmaceutica Nv | Hiv replication inhibiting purine derivatives |
WO2005028479A2 (en) * | 2003-09-25 | 2005-03-31 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting purine derivatives |
EA009734B1 (en) * | 2003-09-25 | 2008-02-28 | Янссен Фармацевтика Н.В. | Hiv replication inhibiting purine derivatives |
WO2005047524A2 (en) | 2003-11-10 | 2005-05-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
EP1682150A2 (en) * | 2003-11-10 | 2006-07-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
US8309555B2 (en) | 2003-11-10 | 2012-11-13 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
US9334481B2 (en) | 2003-11-10 | 2016-05-10 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
US7951592B2 (en) | 2003-11-10 | 2011-05-31 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
EP1682150B1 (en) * | 2003-11-10 | 2012-12-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
WO2005097135A2 (en) * | 2004-04-05 | 2005-10-20 | Novartis Ag | Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives |
WO2005097135A3 (en) * | 2004-04-05 | 2006-02-16 | Novartis Ag | Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
WO2006004636A3 (en) * | 2004-06-28 | 2006-05-26 | Bristol Myers Squibb Co | Fused heterocyclic kinase inhibitors |
US9150543B2 (en) | 2004-07-28 | 2015-10-06 | Janssen Pharmaceutica N. V. | Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase |
US9636341B2 (en) | 2004-07-28 | 2017-05-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US7851480B2 (en) | 2004-11-24 | 2010-12-14 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
AU2006257583B2 (en) * | 2005-06-16 | 2013-01-24 | Zhe Jiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
EP1897882A1 (en) * | 2005-06-16 | 2008-03-12 | Zhe Jiang Medecine Co., Ltd. Xinchang Pharmaceutical Factory | N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
EP1897882A4 (en) * | 2005-06-16 | 2009-12-23 | Zhe Jiang Medecine Co Ltd Xinc | N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
WO2007042298A1 (en) * | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
WO2007042299A1 (en) * | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
US9096542B2 (en) | 2005-12-15 | 2015-08-04 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
US7601713B2 (en) | 2005-12-15 | 2009-10-13 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
US9834568B2 (en) | 2005-12-15 | 2017-12-05 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
US8053434B2 (en) | 2005-12-15 | 2011-11-08 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
US9078896B2 (en) | 2006-01-19 | 2015-07-14 | Janssen Pharmaceutica, N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8664223B2 (en) | 2006-01-19 | 2014-03-04 | Janssen Pharmaceutica N.V | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8957081B2 (en) | 2006-12-08 | 2015-02-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2008081928A1 (en) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Pyrazolopyrimidine compound |
WO2008107444A1 (en) | 2007-03-07 | 2008-09-12 | Boehringer Ingelheim International Gmbh | 9h- purine derivatives and their use in the treatment of proliferative diseases |
US8404674B2 (en) | 2007-03-07 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof |
WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
US7705004B2 (en) | 2007-08-17 | 2010-04-27 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
WO2009026107A1 (en) * | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
FR2929851A1 (en) * | 2008-04-09 | 2009-10-16 | Centre Nat Rech Scient | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE TYROSINE KINASE SYK PROTEIN AND METHOD OF IDENTIFYING SAID MOLECULES |
WO2009133294A3 (en) * | 2008-04-09 | 2010-04-08 | Centre National De La Recherche Scientifique | Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules |
WO2009133294A2 (en) * | 2008-04-09 | 2009-11-05 | Centre National De La Recherche Scientifique | Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules |
US9504676B2 (en) | 2008-04-09 | 2016-11-29 | Centre National De La Recherche Scientifique | Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules |
US8952027B2 (en) | 2008-04-16 | 2015-02-10 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US9579320B2 (en) | 2008-04-16 | 2017-02-28 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US11414410B2 (en) | 2008-04-16 | 2022-08-16 | Alexion Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8937070B2 (en) | 2008-04-16 | 2015-01-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US10533001B2 (en) | 2008-04-16 | 2020-01-14 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8501944B2 (en) | 2008-04-16 | 2013-08-06 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9868729B2 (en) | 2008-04-16 | 2018-01-16 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9139581B2 (en) | 2008-04-22 | 2015-09-22 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009131687A2 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009131687A3 (en) * | 2008-04-22 | 2010-01-07 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9012462B2 (en) | 2008-05-21 | 2015-04-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
WO2010111406A3 (en) * | 2009-03-24 | 2011-07-07 | Myriad Pharmaceuticals, Inc. | Purine derivatives useful as anti - cancer agents |
EA021568B1 (en) * | 2009-12-23 | 2015-07-30 | Такеда Фармасьютикал Компани Лимитед | Fused heteroaromatic pyrrolidinones as syk inhibitors |
KR101790255B1 (en) | 2009-12-23 | 2017-10-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Fused heteroaromatic pyrrolidinones as syk inhibitors |
EP3489236A1 (en) | 2009-12-23 | 2019-05-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of fused heteroaromatic pyrrolidinones |
JP2017008052A (en) * | 2009-12-23 | 2017-01-12 | 武田薬品工業株式会社 | Condensed heteroaromatic pyrrolidinone as syk inhibitor |
EP3825316A1 (en) | 2009-12-23 | 2021-05-26 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2011079051A1 (en) | 2009-12-23 | 2011-06-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
US9181255B2 (en) | 2009-12-23 | 2015-11-10 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as SYK inhibitors |
JP2013515729A (en) * | 2009-12-23 | 2013-05-09 | 武田薬品工業株式会社 | Condensed heteroaromatic pyrrolidinones as SYK inhibitors |
US9108970B2 (en) | 2009-12-23 | 2015-08-18 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones |
JP2018009017A (en) * | 2009-12-23 | 2018-01-18 | 武田薬品工業株式会社 | Condensed heterocyclic aromatic pyrrolidinone as syk inhibitor |
EP2902392A1 (en) | 2009-12-23 | 2015-08-05 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
CN102753548A (en) * | 2009-12-23 | 2012-10-24 | 武田药品工业株式会社 | Fused heteroaromatic pyrrolidinones |
US8440689B2 (en) | 2009-12-23 | 2013-05-14 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9353115B2 (en) | 2011-06-01 | 2016-05-31 | Janus Biotherapeutics, Inc. | Immune system modulators |
AU2012262021B2 (en) * | 2011-06-01 | 2016-07-28 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
US9663514B2 (en) | 2011-06-22 | 2017-05-30 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
EP3040337A4 (en) * | 2013-08-30 | 2017-01-18 | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof |
EP3256475A4 (en) * | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
EP3778605A3 (en) * | 2015-02-13 | 2021-03-10 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
US10711002B2 (en) | 2016-04-21 | 2020-07-14 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
AU2017345736B2 (en) * | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
EP3528816A4 (en) * | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US11396508B2 (en) | 2016-10-21 | 2022-07-26 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
WO2019076817A1 (en) | 2017-10-19 | 2019-04-25 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
US11077111B2 (en) | 2017-10-19 | 2021-08-03 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
WO2019241896A1 (en) * | 2018-06-22 | 2019-12-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1200435B1 (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
RU2277100C2 (en) | Compound, methods for its preparing, pharmaceutical composition, compounds | |
EP1443925B1 (en) | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors | |
AU2006205878B2 (en) | Purine derivatives acting as A2A receptor agonists | |
JP2009542645A (en) | 8-oxoadenine derivatives acting as modulators of TLR7 | |
NZ525875A (en) | Aminothiazoles and their use as adenosine receptor antagonists | |
EP2138497A1 (en) | Novel adenine compound | |
ZA200508603B (en) | Inhibitors of phosphatidylinositol 3-kinase | |
AU2005270314A1 (en) | Pyrazole derivatives for treating conditions mediated by activation of the adenosine A2b or A3 receptor | |
MX2008013523A (en) | Use of 2-(purin-9-yl)-tetrahydofuran-3,4-diol derivatives as adenosine a2a receptor agonists. | |
AU2005206290A1 (en) | Thiazole derivatives as A2b antagonists | |
US6964960B2 (en) | Indoloquinazolinones | |
US6187780B1 (en) | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity | |
CN112778318B (en) | Pyrimidopyrazole derivatives for inhibiting xanthine oxidase activity, and preparation method and application thereof | |
WO2021143843A1 (en) | Crystal of pde3/pde4 dual inhibitor and use thereof | |
WO2018041260A1 (en) | Bromodomain recognition protein inhibitor and preparation method therefor and use thereof | |
WO1999062905A1 (en) | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors | |
US20230303542A1 (en) | Solid forms of a parp14 inhibitor | |
JP2001507711A (en) | Preparation of tetrazolylbenzopyran | |
WO2023221078A1 (en) | Solid forms of a compound for treating or preventing hyperuricemia or gout | |
WO1993015717A1 (en) | Compositions for the treatment of glaucoma | |
JPH06239862A (en) | Xanthine derivative | |
US20110294828A1 (en) | Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200200121 Country of ref document: VN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000953112 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 147455 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2379560 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65677/00 Country of ref document: AU Ref document number: 516667 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/109/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-299 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1262002 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/00234 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/00783 Country of ref document: ZA Ref document number: 200200783 Country of ref document: ZA Ref document number: 008110263 Country of ref document: CN Ref document number: 1020027001276 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/001102 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027001276 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002103305 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10048577 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-299 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2000953112 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000953112 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 65677/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 516667 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 516667 Country of ref document: NZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027001276 Country of ref document: KR |